Tranexamic acid probably leads to higher any thromboembolic event Clinical and radiological assessment compared with placebo (moderate certainty).
Tranexamic acid probably leads to lower surgery Number of participants who underwent surgery compared with placebo (moderate certainty).
It is very uncertain whether tranexamic acid changes transfusion Number needing blood transfusion compared with placebo (very low certainty).
Tranexamic acid probably leads to lower mortality Number of participants who died compared with cimetidine or lansoprazole (moderate certainty).
Tranexamic acid probably leads to lower rebleeding Clinical and endoscopic assessment compared with cimetidine or lansoprazole (moderate certainty).
Tranexamic acid probably leads to lower surgery Number of participants who underwent surgery compared with cimetidine or lansoprazole (moderate certainty).
Tranexamic acid may leads to lower transfusion Number of participants who required at least 1 blood… compared with cimetidine or lansoprazole (low certainty).
Methotrexate probably leads to higher proportion of patients maintaining clinical remission compared with placebo (moderate certainty).
It is very uncertain whether methotrexate changes proportion of patients maintaining clinical remission compared with 6‐mercaptopurine (very low certainty).
Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Etoricoxib showed no clear difference in exacerbation of IBD compared with placebo (low certainty).
Celecoxib showed no clear difference in exacerbation of ulcerative colitis compared with placebo (low certainty).
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).